Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · IEX Real-Time Price · USD
34.67
-1.76 (-4.83%)
Jun 14, 2024, 4:00 PM EDT - Market closed

Celldex Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Year 20232022202120202019 2018 - 1994
Net Income
-141.43-112.33-70.51-59.78-50.88
Upgrade
Depreciation & Amortization
3.012.93.073.934.86
Upgrade
Share-Based Compensation
23.8915.618.953.924.55
Upgrade
Other Operating Activities
7.24-9.91-2.4211.53-4.95
Upgrade
Operating Cash Flow
-107.29-103.73-60.91-40.4-46.42
Upgrade
Capital Expenditures
-1.82-1.76-1.22-1.5-0.71
Upgrade
Change in Investments
-103.9691.7-214.93-96.7217.79
Upgrade
Investing Cash Flow
-105.7889.94-216.16-98.2217.08
Upgrade
Share Issuance / Repurchase
218.464.08272.37171.2316.26
Upgrade
Financing Cash Flow
218.464.08272.37171.2316.26
Upgrade
Net Cash Flow
5.39-9.71-4.6932.6-13.08
Upgrade
Free Cash Flow
-109.11-105.49-62.13-41.9-47.13
Upgrade
Free Cash Flow Margin
-1585.20%-4475.65%-1335.86%-564.86%-1318.95%
Upgrade
Free Cash Flow Per Share
-2.25-2.25-1.45-1.41-3.25
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).